NCT03037632

DCM Precision Medicine Study

Active, enrolled NA Last updated 30 July 2025

What this trial tests

NA trial testing Family Heart Talk Booklet in Idiopathic Dilated Cardiomyopathy in 6,500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 June 2016

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	Ray Hershberger
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	6,500
Start date	7 June 2016
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	26 locations across United States

Drugs / interventions tested

• Family Heart Talk Booklet

Conditions studied

• Idiopathic Dilated Cardiomyopathy — all drugs for Idiopathic Dilated Cardiomyopathy →

Sponsor

Ray Hershberger

Who can join

Eligibility, any sex, with Idiopathic Dilated Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of the DCM Precision Medicine Study are to test the hypothesis that DCM has substantial genetic basis and to evaluate the effectiveness of a family communication intervention in improving the uptake and impact of family member clinical screening.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Variant Interpretation for Dilated Cardiomyopathy: Refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study.
   Morales A, Kinnamon DD, Jordan E, Platt J, et al · · 2020 · cited 103× · PMID 32160020 · DOI 10.1161/circgen.119.002480
2. Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy.
   Huggins GS, Kinnamon DD, Haas GJ, Jordan E, et al · · 2022 · cited 67× · PMID 35103767 · DOI 10.1001/jama.2021.24674
3. Toward Genetics-Driven Early Intervention in Dilated Cardiomyopathy: Design and Implementation of the DCM Precision Medicine Study.
   Kinnamon DD, Morales A, Bowen DJ, Burke W, et al · · 2017 · cited 53× · PMID 29237686 · DOI 10.1161/circgenetics.117.001826
4. Validating an Idiopathic Dilated Cardiomyopathy Diagnosis Using Cardiovascular Magnetic Resonance: The Dilated Cardiomyopathy Precision Medicine Study.
   Haas GJ, Zareba KM, Ni H, Bello-Pardo E, et al · · 2022 · cited 29× · PMID 35240856 · DOI 10.1161/circheartfailure.121.008877
5. Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study.
   Hofmeyer M, Haas GJ, Jordan E, Cao J, et al · · 2023 · cited 23× · PMID 37641966 · DOI 10.1161/circulationaha.123.064847
6. Effectiveness of the <i>Family Heart Talk</i> Communication Tool in Improving Family Member Screening for Dilated Cardiomyopathy: Results of a Randomized Trial.
   Kinnamon DD, Jordan E, Haas GJ, Hofmeyer M, et al · · 2023 · cited 11× · PMID 36938756 · DOI 10.1161/circulationaha.122.062507
7. Molecular Diagnostics in Heart Failure: From Biomarkers to Personalized Medicine.
   Țica O, Țica O. · · 2025 · cited 8× · PMID 40722556 · DOI 10.3390/diagnostics15141807
8. TTR variants in patients with dilated cardiomyopathy: An investigation of the DCM Precision Medicine Study.
   Trachtenberg BH, Jimenez J, Morris AA, Kransdorf E, et al · · 2022 · cited 7× · PMID 35438637 · DOI 10.1016/j.gim.2022.03.011